RVTY: Operating Margins And Buyback Plan Will Drive Share Recovery Ahead

AN

AnalystConsensusTarget

AnalystConsensusTarget

Not Invested

Based on Analyst Price Targets

Published

21 Aug 24

Updated

29 Nov 25

Views

71

n/a

n/a

AnalystConsensusTarget's Fair Value

n/a

1Y

-12.9%

7D

-1.3%

Loading

1Y

-12.9%

7D

-1.3%

You can edit this narrative until Nov 30 11:05 AM. Then, changes will post as Updates.

Author's Valuation

US$113.6714.0% undervalued

AnalystConsensusTarget Fair Value

Shared on 29 Nov 25

RVTY: Buyback Program and Guidance Outlook Will Shape Next Phase

Analysts have increased their price target for Revvity to $105 from previous levels. They cite achievable Q4 guidance and an improved profit outlook, despite mixed quarterly results.

Shared on 15 Nov 25

RVTY: Recent Buyback Activity and Expanded Partnership Will Drive Near-Term Momentum

Revvity's analyst price target has increased from $99 to $105 per share, as analysts cite improving guidance for the upcoming quarter and stronger than expected recent performance, while noting that some risks remain. Analyst Commentary Analyst sentiment towards Revvity has shifted positively in recent weeks, reflecting improved financial guidance and resilient performance.

Shared on 31 Oct 25

Fair value Increased 0.89%

Analysts have slightly raised their fair value estimate for Revvity by $1 to $113.67. They cite more achievable Q4 guidance and improved margin prospects following the company's recent earnings updates.

Shared on 17 Oct 25

Fair value Decreased 2.19%

The consensus analyst price target for Revvity has decreased from $115.19 to $112.67. This change reflects lowered profit margin forecasts, slower revenue growth expectations, and continued market headwinds highlighted in recent research reports.

Shared on 03 Oct 25

Fair value Decreased 1.39%

Analysts have slightly reduced their price target for Revvity by $1.63 to $115.19. They cite cautious optimism, as stable core markets are offset by ongoing sector uncertainties and revised forecasts for a slower recovery.

Shared on 07 May 25

Fair value Decreased 14%

Shared on 30 Apr 25

Fair value Increased 0.43%

AnalystConsensusTarget has increased revenue growth from 5.3% to 6.0% and decreased future PE multiple from 38.3x to 33.2x.

Shared on 23 Apr 25

Fair value Decreased 1.85%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 16 Apr 25

Fair value Decreased 3.91%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 09 Apr 25

Fair value Increased 16%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 02 Apr 25

Fair value Decreased 12%

Shared on 26 Mar 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 19 Mar 25

Fair value Decreased 0.064%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 10 Mar 25

Fair value Increased 13%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

AnalystConsensusTarget Fair Value

US$113.67

14.0% undervalued

Future estimation in

Growth p.a.

Growth p.a.

%

Decrease

Increase

Current revenue growth rate

5.02%

Life Sciences revenue growth rate

0.26%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

%

0

Decrease

Increase

Current discount rate

8.43%

Calculation

US$661.87m

Earnings '28

x

20.78x

PE Ratio '28

=

US$13.76b

Market Cap '28

US$13.76b

Market Cap '28

/

95.17m

No. shares '28

=

US$144.55

Share Price '28

US$144.55 Share Price '28

Discounted to 2025 @ 8.41% p.a.

=

US$113.46

Fair Value '25